LONDON–(BUSINESS WIRE)–March 21, 2022–
Ixaka Ltd, an integrated cell and gene therapy company, today announces the expansion of its IP portfolio to enable a broad range of applications for its polymer-targeted nanoparticle (TNP)-based gene delivery platform in multiple therapeutic areas. Extensive intellectual property enables development of therapies encapsulating any cargo, including mRNA, plasmids, and adenovirus-associated virus (AAV), and gene-editing technologies as well as vector-based therapies lentivirals.
Ixaka’s TNP – composed of a proprietary polymer capsule (‘OM-PBAE’ polymers (end-modified oligopeptide poly β-amino ester polymers)) directed to specific cells through capsule-attached targeting agents (an aptamer-based targeting moiety) and cell-targeted efficient transduction (use of cell-specific promoter lentiviral vectors). This targeting allows targeted nanoparticles to be directed to specific cells allowing beneficial gene transduction to occur directly within a patient’s body. The technology is currently being applied as a gene delivery platform to generate CAR T-cell therapies live for hematological malignancies, with potential for improved efficacy and safety compared to similar products currently on the market or in development. The expanded intellectual property allows a wide range of cargoes to be encapsulated, providing greater flexibility to design novel therapies optimized for specific diseases.
A new agreement expands the use of its OM-PBAE polymers for the encapsulation of a wide range of cargoes for use in any therapeutic area, including mRNA, plasmids and any other vector in addition to vectors lentivirals and AAV.
Extension of License Agreement Opens Door for Expansion of Ixaka’s TNP Platform, Allowing Use of OM-PBAE Polymer Capsules for Multiple Cargo Delivery with Choice of Technology of genetic modification adapted to each disease. Potential applications include drug delivery for oligonucleotides such as DNA, RNA, and siRNA, plasmids, small molecules, and gene editing using tools such as CRISPR–Cas9 , zinc finger or megaTALS – enabling Ixaka to expand its therapeutic pipeline.
Joe Dupere, CEO of Ixaka, commented:
“This IP agreement further strengthens Ixaka’s rapidly growing IP portfolio, underscoring the pioneering nature and vast potential of our targeted nanoparticle technology. The platform already shows great potential in the generation of CAR-T cells live for CD19 blood cancers. With an array of other possible applications, we will now seek collaborations for our future pipeline, which could encompass solid tumors, rare genetic diseases, autoimmune diseases, broader immunotherapy applications, editing of genes, immunodiagnostics and vaccines.
Overview of the intellectual property portfolio
Building a strong and extensive IP portfolio is at the heart of Ixaka’s development strategy. The Company’s ongoing R&D and future clinical data will allow additional patent applications to be filed in several territories.
Ixaka’s current intellectual property portfolio contains 1 patent family for its multi-cell therapy platform and 11 patent families for its TNP platform, covering all key components of the technology, including a proprietary polymer, a bald lentiviral vector, a T-cell specific promoter and an aptamer-based targeting agent. The wallet also offers protection across a wide geographic range (including Europe, USA, Canada, Mexico, Brazil, China, India, Korea, Japan, Australia).
The patent relates to products developed under a licensing agreement between Ixaka (formerly aratinga.bio), Sagetis Biotech (“Sagetis”) and universities (Institut Quimic de Sarria CETS Fundacio Privada and Institut d’Investigacions Biomediques).
Ixaka is a cell and gene therapy company focused on using the body’s natural powers to cure disease.
Ixaka’s proprietary technologies enhance the natural therapeutic power of cells by increasing the presence of healing cells at the site of disease, or by directly modifying cells in the body to improve disease targeting and enhance their restorative effect.
Ixaka’s technologies – concentrated multicellular therapies and nanoparticle-based therapeutics – demonstrate potential for the treatment of a wide range of serious diseases in the fields of oncology, cardiovascular, neurological and ocular diseases and genetic disorders.
Ixaka has offices in London, UK, with R&D and manufacturing operations in Seville, Spain and Paris, France, as well as additional manufacturing capacity in Frankfurt, Germany.
For more information, visit www.ixaka.com
Connect with us: Twitter: https://twitter.com/Ixaka_Ltd ; LinkedIn: https://www.linkedin.com/company/ixaka-limited
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220321005423/en/
CONTACT: For more information, please contact: Ixaka
+44 (0) 203 7007 480
www.ixaka.comInstinctive Partners (media enquiries)
Tim Watson / Siobhan Sandford / Sirine Zeineh / Grace Rutter
+44 7837 674 500
KEYWORD: UNITED KINGDOM EUROPE
INDUSTRY KEYWORD: HEALTH GENETIC RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
Copyright BusinessWire 2022.
PUBLISHED: 03/21/2022 05:00 / DISK: 03/21/2022 05:02